<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892421</url>
  </required_header>
  <id_info>
    <org_study_id>R-2018-3501-014</org_study_id>
    <nct_id>NCT03892421</nct_id>
  </id_info>
  <brief_title>Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma</brief_title>
  <official_title>Safety and Efficacy of an Outpatient Schedule of Rituximab, Cytarabine, Carboplatin, and Dexamethasone in Relapsed/Refractory Non-Hodgkin Lymphoma. Phase I/II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La Raza Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La Raza Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the efficacy and safety of a combination of the
      anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and
      Carboplatin; delivered in an outpatient setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The R-DHAP (Rituximab, Dexamethasone, Cytarabine, and Cisplatin) schedule includes high-dose
      cytarabine every 12 hours and requires careful monitoring of renal toxicity because of
      cisplatin. These conditions limit the use of this protocol in an outpatient setting.

      The S phase of lymphoma cells is longer than 12 hours, then cytarabine can be used daily
      without reduction of the antineoplastic effect. Carboplatin does not have remarkable renal
      toxicity so is not necessary to monitor blood chemistry or IV fluids during its
      administration.

      The study hypothesis is that modifications to the original R-DHAP protocol, using cytarabine
      on a daily basis and the substitution of cisplatin by carboplatin can preserve the efficacy,
      reducing the incidence of renal events. The investigators hypothesize that those
      modifications can make the schedule more suitable for an outpatient administration in
      relapsed or refractory non-Hodgkin lymphoma patients.

      After 3 cycles of chemotherapy, the overall response and the incidence of adverse events will
      be evaluated.

      In order to achieve the purpose of this trial, 130 participants will be included.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>63 days</time_frame>
    <description>The percentage of patients which showed either a partial remission (PR), or a complete remission (CR) after study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hematological toxicities &gt; grade 2 by Common Terminology Criteria V4.0</measure>
    <time_frame>63 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Modified DHAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m²</description>
    <arm_group_label>Modified DHAP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC5</description>
    <arm_group_label>Modified DHAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine Injection</intervention_name>
    <description>Cytarabine 2000 mg/m² qd 2 days</description>
    <arm_group_label>Modified DHAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg</description>
    <arm_group_label>Modified DHAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim 0.3 MG/ML</intervention_name>
    <description>One subcutaneous injection daily for 5 days</description>
    <arm_group_label>Modified DHAP</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of recurrent or refractory B-cell non-Hodgkin lymphoma

          -  Performance status: Eastern Cooperative Oncology Group 0-2

          -  At least three weeks from last chemotherapy

          -  Toxicities by Common Terminology Criteria Version 4.0 ≤ 1

          -  Glomerular filtration rate &gt;50 ml/min

          -  Women of childbearing potential must use effective methods of contraception

        Exclusion Criteria:

          -  Post-transplant relapse of lymphoma

          -  Central nervous system involvement of lymphoma

          -  Serious infections

          -  Known allergies to one or more of the experimental drugs

          -  Diabetes with glucose &gt;200 mg/dl

          -  Pregnant or lactating females

          -  Known HIV or B Hepatitis positivity

          -  Known allergies to filgrastim
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Officials H Caballero, MD Ms</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Department La Raza Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alvaro H Caballero, MD MS</last_name>
    <phone>5528552014</phone>
    <email>alvheca@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Especialidades Centro Medico La Raza</name>
      <address>
        <city>Mexico City</city>
        <state>Azcapotzalco</state>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro H Caballero, MD MS</last_name>
      <phone>5528552014</phone>
      <email>alvheca@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22.</citation>
    <PMID>3334893</PMID>
  </reference>
  <reference>
    <citation>Momparler RL. Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. Exp Hematol Oncol. 2013 Aug 6;2:20. doi: 10.1186/2162-3619-2-20. eCollection 2013.</citation>
    <PMID>23919448</PMID>
  </reference>
  <reference>
    <citation>Yanik G, Yousuf N, Miller MA, Swerdlow SH, Lampkin B, Raza A. In vivo determination of cell cycle kinetics of non-Hodgkin's lymphomas using iododeoxyuridine and bromodeoxyuridine. J Histochem Cytochem. 1992 May;40(5):723-8.</citation>
    <PMID>1573252</PMID>
  </reference>
  <reference>
    <citation>Sandlund JT, Santana VM, Hudson MM, Onciu M, Head D, Murry DJ, Ribeiro R, Wallace D, Rencher R, Pui CH. Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer. 2008 Aug 15;113(4):782-90. doi: 10.1002/cncr.23630.</citation>
    <PMID>18618501</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 24, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>La Raza Medical Center</investigator_affiliation>
    <investigator_full_name>Alvaro Hernandez Caballero MD MS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

